Heart Failure: SGLT inhibitors in Clinical Practice – Are we overthinking it?

Many more patients could have a meaningful lower risk of HF events.

• Discuss a spectrum of clinical scenarios, along the course of the HF journey.
• All patients with HF are at high risk of the next HF event. Giving just “some” GDMTs is not enough!
• Addressing myths around SGLT inhibitors in clinical practice – what the evidence shows. 
• Evidence-based overview of what can be expected from an SGLT1-2 inhibitor like INPEFA® (sotagliflozin) in patients with HF

Sponsored by Lexicon Pharmaceuticals, Inc.